News Briefs

✦ The U.S. Supreme Court denied a petition from Novartis AG’s Sandoz unit to review the 2020 Federal Circuit decision to uphold two patents of Amgen Inc.’s Enbrel (etanercept). The FDA approved Sandoz’s Enbr...
0 Comments
© 2025 MMIT

News Briefs

✦ The FDA’s Oncologic Drugs Advisory Committee voted to keep most indications for a handful of immune checkpoint inhibitors that target programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and received acce...
0 Comments
© 2025 MMIT

Pilot Program Targets SDOH Barriers for Members With MS

Recently, health insurers have begun focusing on social determinants of health (SDOH) and the role these factors play on health outcomes. Then the COVID-19 pandemic put even more of a spotlight on the issue, disprop...
0 Comments
© 2025 MMIT

Precision Oncology Solution Aims to Improve Patient Outcomes

With more and more oncolytics targeting specific alterations in tumors, the area of precision oncology is developing rapidly. To help bring some insight into this market, Magellan Rx Management, a division of Magell...
0 Comments
© 2025 MMIT

Study Finds Wide Variation in Payers’ CAR-T Drug Costs

Chimeric antigen receptor T cell (CAR-T) therapies have been available in the U.S. since August 2017. While the list prices for the one-time treatments are known, a recent study from Prime Therapeutics LLC examined ...
0 Comments
© 2025 MMIT

Report: Specialty Drug Spending May Be Slowed by Biosimilars

Based on invoice price levels, the IQVIA Institute for Human Data Science anticipates that the global medicine market will experience a 3% to 6% compound annual growth rate (CAGR) through 2025. Oncology and immunolo...
0 Comments
© 2025 MMIT

Study Finds Good Adherence, Low ADE Rates With Oral DMTs

The multiple sclerosis (MS) therapeutic class boasts more than 20 disease modifying therapies (DMTs) that have various routes of administration. A recent study of oral therapies to treat relapsing-remitting MS (RRMS...
0 Comments
© 2025 MMIT

Integrated Medical, Pharmacy Claims Give Full View of AI Class

Some companies that analyze specialty drug spend do so with a focus solely on the pharmacy benefit. This approach, however, may fail to take into account a significant amount of medical benefit spending within certa...
0 Comments
© 2025 MMIT

New FDA Specialty Approvals

✦ April 6: The FDA approved a new dosing regimen for Eli Lilly and Co.’s Erbitux (cetuximab) of 500 mg/m2 as a 120-minute infusion every two weeks as a single agent or in combination with chemotherapy for people...
0 Comments
© 2025 MMIT

News Briefs

The FDA’s Oncologic Drugs Advisory Committee voted to keep most indications for a handful of immune checkpoint inhibitors that target programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and received accelera...
0 Comments
© 2025 MMIT